Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

2.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.5K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

74.1K
Overview
74.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Inflammatory immune modulators of AML lung infiltration and respiratory failure.

Nature immunology·2026
Same author

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

JCO oncology practice·2026
Same author

Loss of AMBRA1 activates MAPK and angiogenesis signaling pathways in melanoma cells.

FEBS open bio·2026
Same author

RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcoma.

Blood cancer discovery·2026
Same author

Interactions of outer membrane lipoproteins <i>P. aeruginosa</i> PA3214 and <i>E. coli</i> PqiC with their MCE protein binding partners, PA3213 and PqiB.

bioRxiv : the preprint server for biology·2026
Same author

Lymphatic egress recycles tumor-experienced effector CD8 T cells to sustain immune surveillance.

bioRxiv : the preprint server for biology·2026
Same journal

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
查看所有相关文章

相关实验视频

Updated: Sep 18, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.1K

人工智能算法预测对免疫检查点抑制剂的反应

Faisal Fa'ak1,2, Nicolas Coudray3,4, George Jour5

  • 1Division of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri.

Clinical cancer research : an official journal of the American Association for Cancer Research
|June 24, 2025
PubMed
概括
此摘要是机器生成的。

机器学习模型可以预测黑色素瘤患者对免疫检查点抑制剂 (ICI) 的反应. 新型瘤特征如上皮质组织学和低瘤-肌瘤比率与ICI治疗改善的生存结果有关.

更多相关视频

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

4.9K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.4K

相关实验视频

Last Updated: Sep 18, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.1K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

4.9K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.4K

科学领域:

  • 在瘤学瘤学.
  • 计算病理学计算病理学
  • 免疫治疗是一种免疫疗法.

背景情况:

  • 免疫检查点抑制剂 (ICI) 已经改变了癌症护理,但患者的反应有很大的差异.
  • 由于缺乏可概括的生物标志物,预测ICI反应和不良事件仍然具有挑战性.
  • 之前的工作建立了一个监督机器学习 (ML) 模型,用于转移性黑色素瘤的ICI反应.

研究的目的:

  • 验证和扩展监督ML算法的可通用性,用于预测较大的黑色素瘤队列中的ICI反应.
  • 开发一种自我监督的ML模型,以识别与ICI治疗后患者存活相关的组织学特征.
  • 在辅助性和转移性黑色素瘤环境中调查ICI反应和生存率.

主要方法:

  • 从639名III/IV期黑色素瘤患者的治疗前治疗血素和素幻灯片的分析,这些患者接受了ICI (抗CTLA-4,抗PD-1或组合) 治疗.
  • 在转移性黑色素瘤队列上测试监督ML算法的概括性.
  • 开发一种自我监督的ML模型,以将组织学形态与无进展和整体存活相关联.

主要成果:

  • 监督的ML算法在预测ICI治疗反应时实现了0.72的AUC.
  • 一个深层卷积神经网络将患者分为高风险和低风险组,以无进展生存 (P < 0.0001).
  • 在表皮质组织学,低瘤-肌瘤比率和ICI治疗后改善的生存率之间发现了新的关联.

结论:

  • 开发的ML算法在预测转移性黑色素瘤的ICI治疗反应方面表现出普遍性.
  • 这项研究首次确定了与接受ICI的患者的整体存活率相关的特定瘤组织学特征.
  • 这些发现为将基于ML的生物标志物纳入临床实践为个性化黑色素瘤治疗铺平了道路.